CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Athersys Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Athersys Inc
3201 Carnegie Avenue
Phone: (216) 431-9900p:216 431-9900 CLEVELAND, OH  44115  United States Ticker: ATHX ATHX
Filed for Bankruptcy on 1/5/2024
Case #24-10043, filed in the U.S. Bankruptcy Court for the Northern District of Ohio (Cleveland)
On 9/24/2024, the voluntary petition for the Company for reorganization under Chapter 11 was converted to Chapter 7
This entity represents the bankrupt estate of the former businesses (assets) of Athersys Inc that were not sold to HEALIOS K.K. on 4/3/2024
Business Summary
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. The MultiStem clinical product is developed from a special class of stem cells called Multipotent Adult Progenitor Cells. The Company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
9995 Non-operating establishments

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Interim Chief Financial Officer, Director KaseyRosado 50 4/1/2024 8/4/2022

Subsidiaries
Business Name Address City State/Province Country
Advanced Biotherapeutics, Inc. 1625 Rockwell Avenue Cleveland OH United States

Business Names
Business Name
ABT Holding Company
Advanced Biotherapeutics, Inc.
AHYS
6 additional Business Names available in full report.

General Information
Number of Employees: 24 (As of 12/31/2022)
Outstanding Shares: 61,718,765 (As of 11/21/2023)
Shareholders: 414
Stock Exchange: OTC
Federal Tax Id: 341830213
Fax Number: (216) 361-9495


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, January 7, 2025